MedElevator
Войти в исследования Juntendo medical journal · 2025
Evaluation of Plasma Opioid and Serum Lipocalin-2 Levels in Pruritic Skin Diseases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawamura Mayu, Kamata Yayoi, Komiya Eriko, Moniaga Catharina Sagita, Takahashi Nobuaki, Kaneko Takahide, Suga Yasushi, Tominaga Mitsutoshi, Takamori Kenji
Аннотация
OBJECTIVES: Although the opioid system is critical for regulating itch within the central nervous system, its role in managing severe, treatment-resistant itch related to skin diseases is unclear. Serum lipocalin-2 (LCN-2) levels are associated with the visual analogue scale score of itch in patients with psoriasis vulgaris (PSO), but not other itchy skin diseases. Therefore, we herein investigated the relationship between opioids and LCN-2 with itch in pruritic skin diseases.
METHODS: We assessed plasma levels of β-endorphin and dynorphin A and serum levels of LCN-2 in patients with pruritic skin diseases using enzyme-linked immunosorbent assays.
RESULTS: Plasma dynorphin A levels were significantly reduced in patients with urticaria, and asteatotic dermatitis (AsD), while β-endorphin levels were significantly elevated in those with AsD. The plasma β-endorphin-to-dynorphin A ratio was markedly higher in AsD patients than in healthy controls. Among the patients examined, only those with PSO had significantly elevated serum LCN-2 levels, which correlated with VAS and severity index scores and also with the area of affected skin.
CONCLUSIONS: The present results suggest that the ratio of plasma opioids is involved in itch control in AsD patients, and serum LCN-2 levels may be a biomarker for itch and its severity in those with PSO.
METHODS: We assessed plasma levels of β-endorphin and dynorphin A and serum levels of LCN-2 in patients with pruritic skin diseases using enzyme-linked immunosorbent assays.
RESULTS: Plasma dynorphin A levels were significantly reduced in patients with urticaria, and asteatotic dermatitis (AsD), while β-endorphin levels were significantly elevated in those with AsD. The plasma β-endorphin-to-dynorphin A ratio was markedly higher in AsD patients than in healthy controls. Among the patients examined, only those with PSO had significantly elevated serum LCN-2 levels, which correlated with VAS and severity index scores and also with the area of affected skin.
CONCLUSIONS: The present results suggest that the ratio of plasma opioids is involved in itch control in AsD patients, and serum LCN-2 levels may be a biomarker for itch and its severity in those with PSO.